Synergy Pharmaceuticals (FRA:S90) ROCE % : 0.00% (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Synergy Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2018 was 0.00%.

Synergy Pharmaceuticals ROCE % Historical Data

The historical data trend for Synergy Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals ROCE % Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

ROCE %

Get a 7-Day Free Trial

-141.15

-80.62

-77.46

-189.02

-226.45

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
ROCE %	Get a 7-Day Free Trial															-216.97	-127.53	-138.05	-156.79	-

Synergy Pharmaceuticals ROCE % Calculation

Synergy Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2017 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	-187.758	/	( ( (85.18 - 27.9)	+	(140.782 - 32.234) )	/ 2 )
	=	-187.758	/	( (57.28	+	108.548)	/ 2 )
	=	-187.758	/	82.914
	=	-226.45 %

Synergy Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2018 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2018 )		(Q: Jun. 2018 )		(Q: Sep. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2018 )		(Q: Jun. 2018 )		(Q: Sep. 2018 )
	=	-101.496	/	( ( (82.694 - 28.76)	+	(71.164 - 135.344) )	/ 2 )
	=	-101.496	/	( ( 53.934	+	-64.18 )	/ 2 )
	=	-101.496	/	-5.123
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2018) EBIT data.

Synergy Pharmaceuticals (FRA:S90) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Synergy Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines